

WATSON PHARMACEUTICALS INC
Form 8-K
May 12, 2010

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

May 7, 2010

WATSON PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Its Charter)

Nevada

001-03305

95-3872914

**(State or Other Jurisdiction
of Incorporation)**

(Commission File Number)

**(IRS Employer
Identification No.)**

**311 Bonnie Circle
Corona, California**

92880

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code: (951) 493-5300

(Former name or former address, if changed since last report): Not applicable.

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 7, 2010, the Annual Meeting of the Stockholders of Watson Pharmaceuticals, Inc. (the Company) was held in Parsippany, NJ. The following directors were elected to the Company s Board of Directors for a term of three years expiring at the Annual Meeting of Stockholders in 2013:

	For	Against	Abstain	Broker Non-Votes
Paul M. Bisaro	90,923,656	606,242	3,111,548	9,355,424
Christopher W. Bodine	91,944,566	574,887	2,121,993	9,355,424
Michel J. Feldman	86,308,424	2,094,404	6,238,618	9,355,424
Fred G. Weiss	72,703,042	1,243,396	20,695,008	9,355,424

In addition to voting to elect the aforementioned directors, the Company s stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company s independent registered public accounting firm for the fiscal year ending December 31, 2010. The results of the vote were as follows:

	For	Against	Abstain
Ratification of Appointment of PricewaterhouseCoopers LLP	101,281,586	2,608,720	106,564

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 12, 2010

WATSON PHARMACEUTICALS, INC.

By: /s/ David A. Buchen

Name: David A. Buchen

Title: Senior Vice President, General
Counsel and Secretary